Literature DB >> 7458082

Fever response of patients on therapy for pulmonary tuberculosis.

S S Kiblawi, S J Jay, R B Stonehill, J Norton.   

Abstract

The course of fever was examined in 75 patients with pulmonary tuberculosis treated with modern chemotherapy. Sixteen patients (21%) were afebrile and differed from 59 febrile patients (79%) by having lower incidences of the following: symptoms (p < 0.02), alcoholism (p < 0.01), lung cavitation (p < 0.01), "far advanced disease" (p < 0.05), and sputum smears containing "numerous" acid-fast bacilli (p < 0.01). Resolution of fever was variable (mean, 16 days; median, 10 days; range, 1 to 109 days). Thirty-eight patients (64%) became afebrile within 2 wk (group 1); 21 (36%) had fever for longer than 2 wk (group 2). Far advanced disease and high temperature (> 38.8 degrees C) on admission were more frequent in group 2 (p < 0.05 and p < 0.01, respectively). However, the groups did not differ in demographic features or in the frequency of symptoms on admission, alcoholism, lung cavitation, numerous acid-fast bacilli on sputum smears, or coexisting bacterial respiratory infection. Antimicrobial drug treatment of presumed coexistent bacterial infection in 19 febrile patients did not influence the course of fever. Analysis of variance and covariance were used to compare the independent effects of various antituberculosis drug regimens on the course of fever; no significant differences were observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7458082     DOI: 10.1164/arrd.1981.123.1.20

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda.

Authors:  E Namukwaya; F N Nakwagala; F Mulekya; H Mayanja-Kizza; R Mugerwa
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

2.  Clinical investigation of pulmonary Mycobacterium avium complex infection in human T lymphotrophic virus type I carriers.

Authors:  W Matsuyama; A Mizoguchi; F Iwami; Y Koreeda; J Wakimoto; H Kanazawa; S Mori; M Kawabata; H Fukunaga; M Osame
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

3.  PROLONGED FEVER DURING THE TREATMENT OF PULMONARY TUBERCULOSIS.

Authors:  Deepak Rosha
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Paradoxical deterioration during the course of antituberculous treatment.

Authors:  Ibrahim Koral Onal; Yusuf Bayraktar; Serhat Unal
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

5.  Suppression of prolonged fever during treatment of pulmonary tuberculosis: importance of using twice versus single daily dose of prednisolone.

Authors:  K F Chung; P D Snashall
Journal:  Postgrad Med J       Date:  1983-06       Impact factor: 2.401

6.  A stepwise guide for treating tuberculosis.

Authors:  S C Deresinski
Journal:  West J Med       Date:  1984-10

7.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

8.  Tuberculosis associated with Mycobacterium tuberculosis Beijing and non-Beijing genotypes: a clinical and immunological comparison.

Authors:  Yong-Jiang Sun; T K Lim; Adrian Kheng Yeow Ong; Benjamin Choon Heng Ho; Geok Teng Seah; Nicholas I Paton
Journal:  BMC Infect Dis       Date:  2006-07-05       Impact factor: 3.090

9.  Delayed diagnosis of extrapulmonary tuberculosis presenting as fever of unknown origin in an intermediate-burden country.

Authors:  Jeong-Han Kim; Eu Suk Kim; Kang-Il Jun; Hyun Gul Jung; Ji Hwan Bang; Pyeong Gyun Choe; Wan Beom Park; Kyoung-Ho Song; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh; Sang-Won Park
Journal:  BMC Infect Dis       Date:  2018-08-28       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.